Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: Eotaxin (plasma)

Search for Biomarkers


Eotaxin (plasma)



Human K2 EDTA Plasma

Disease State:



Required Sample Volume:

50 µL/well


LLOQ: 12 pg/mL
ULOQ: 3,160 pg/mL

Biological or Clinical Significance:

Human eotaxin (Eot) is an 8.4 kDa, 74 amino acid (aa) residue polypeptide that is produced by a number of normal cells and cell lines.3, 4 Molecules in this group are characterized by the presence of four cysteines, the first two of which are immediately adjacent. To date, human members of this group include MCP-1, MCP-2, MCP-3, MIP-1 alpha, MIP-1 beta, RANTES and I-309,8 and Eot.

Eot activity is limited to eosinophils. For eosinophils, Eot has been proposed to be both an activator and chemoattractor. As an activator, Eot initiates actin polymerization intracellularly, an event that is a prerequisite to chemotaxis, and induces the production of reactive oxygen species, thereby playing a role as a mediator of inflammation.19, 20 It appears then that Eot alone has the ability to selectively prime eosinophils for chemotaxis, to direct their migration/chemotaxis, and to activate inflammatory activity in the cells attracted.


Speak to a Scientist

    What would you like to discuss?

    With whom will we be speaking?

    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

    Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.

    biomarker services


    See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

    Explore our services

    case studies

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

    Read our case studies